Clinical Trials Browser

Completed × Ovarian Neoplasms × fludarabine × Clear all

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT04319757 2024-12-05

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors

Phase 1 Completed

12 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03287674 2023-03-01

TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer

Phase 1/2 Completed

7 enrolled 10 charts

Gynecologic

Ovarian Neoplasms

NCT02096614 2021-06-18

Investigator Initiated Phase 1 Study of TBI-1201

Phase 1 Completed

18 enrolled

DermatologicGastrointestinalGynecologicHead & Neck

Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms

NCT01105650 2017-12-28

MT2009-30

Phase 2 Completed

13 enrolled 11 charts

BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02118285 2017-12-05

Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

Phase 1 Completed

2 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02482090 2017-08-16

TIL Therapy for Metastatic Ovarian Cancer

Phase 1 Completed

6 enrolled

Gynecologic

Ovarian Neoplasms

Clinical Trials

ACTolog

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors

TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer

Investigator Initiated Phase 1 Study of TBI-1201

MT2009-30

Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

TIL Therapy for Metastatic Ovarian Cancer